Kondo et al.’s clinical study demonstrated that treatment of unresectable or recurrent pancreatic cancer with MUC1 peptide-pulsed dendritic cells (MUC1-DC) and activated cytotoxic T lymphocytes (MUC1-CTL) induced immune responses, achieving complete remission in one patient and stability in five, with an extended average survival time to 9.8 months, without observing severe toxic reactions. This evidence concerns the gene MUC1 and familial pancreatic carcinoma.